Spectrum Pharmaceuticals hired James Shields as SVP and chief commercial officer. He will be responsible for growing Spectrum’s Zevalin and Fusilev brands and making launch preparations for the firm’s other late-stage drugs. Shields’ oncology sales experience includes serving as VP of sales for oncology and injectable products for MGI Pharmaceuticals and VP of sales and marketing of oncology for Supergen. He also held positions of increasing responsibility with several pharmaceutical companies, including Centocor, Bristol-Myers Squibb, ICI and Stuart Pharmaceuticals. Shields was most recently with Teva.